Supplementary Information

Autophagy deficiency leads to protection from obesity and insulin resistance by inducing Fgf21 as a ‘mitokine’

Kook Hwan Kim, Yeon Taek Jeong, Hyunhee Oh, Seong Hun Kim, Jae Min Cho, Yo-Na Kim, Su Sung Kim, Do Hoon Kim, Kyu Yeon Hur, Hyoung Kyu Kim, TaeHee Ko, Jin Han, Hong Lim Kim, Jin Kim, Sung Hoon Back, Masaaki Komatsu, Hsiuchen Chen, David C. Chan, Morichika Konishi, Nobuyuki Itoh, Cheol Soo Choi & Myung-Shik Lee

<CONTENTS>

Supplementary Results
Supplementary Figures
Supplementary Methods
Supplementary References
SUPPLEMENTARY RESULTS

Increased Fgf21 in mice fed leucine-deficient diet

To evaluate the role of mitochondrial stress-Atf4-Fgf21 axis in more physiologically relevant models, we challenged mice with calorie-restricted (35% reduction of calorie intake) diet as a nutrient restriction model or leucine-deficient diet as a nutrient deficiency model. Body and fat weights were significantly reduced in both leucine-deficient diet-fed and calorie-restricted diet-fed C57BL/6 mice compared to respective control diet-fed C57BL/6 mice, which was accompanied by enhanced glucose tolerance (Supplementary Fig. 11a–c and data not shown).

Notably, serum FGF21 concentration was increased in mice fed leucine-deficient diet compared to mice fed control diet (Supplementary Fig. 11d). However, we did not observe change of Fgf21 concentration in mice fed calorie-restricted diet (data not shown), in contrast to a recent paper showing a mild increase of Fgf21 after calorie-restricted diet. Differences in experimental procedures (50% vs. 35% reduction of calorie intake) might explain discrepant results. In addition, we found increased Fgf21 mRNA expression and Atf4 activation in the liver of mice fed leucine-deficient diet compared to mice fed control diet, consistent with a recent paper, while such changes were absent in skeletal muscle (Supplementary Fig. 11e), suggesting that the activation of hepatic Atf4-Fgf21 axis contributes to the increased serum Fgf21 concentration in mice fed leucine-deficient diet. However, the expression of Fgf21 and Atf4 was not changed in the liver and skeletal muscle of mice fed calorie-restricted diet compared to mice fed control diet (data not shown). Furthermore, mtOxPhos gene expression was downregulated in the liver of mice fed leucine-deficient diet compared to mice fed control diet (Supplementary Fig. 11f).

Notably, the rate of \textit{ex vivo} \( \beta \)-oxidation was increased in WAT and BAT of mice fed leucine-
deficient diet compared to mice fed control diet (Supplementary Fig. 11g), although the difference in WAT was marginal ($P = 0.056$). However, there were no differences in the rate of β-oxidation in skeletal muscle and liver between the two groups (data not shown). Ucp1 gene expression in WAT and BAT was also upregulated in mice fed leucine-deficient diet compared to mice fed control diet (data not shown). Thus, these results suggest that increased Fgf21 enhances β-oxidation and thermogenesis, leading to reduced fat mass and enhanced glucose tolerance in mice fed leucine-deficient diet. To prove this possibility, we challenged $Fgf21^{+/−}$ mice with leucine-deficient diet. In $Fgf21^{−/−}$ mice fed leucine-deficient diet, body or fat weight loss and enhanced glucose tolerance were remarkably less pronounced compared to $Fgf21^{+/+}$ mice fed leucine-deficient diet (Supplementary Fig. 11h–j), suggesting that increased Fgf21 partially contributes to the changes of metabolic profile in mice fed leucine-deficient diet. In contrast, there were no differences in the loss of body and fat weights, and glucose tolerance between $Fgf21^{−/−}$ and $Fgf21^{+/+}$ mice fed calorie-restricted diet (data not shown). Although it was recently reported that mice fed leucine-deficient diet exhibit reduced fat mass and increased energy expenditure$^3$, molecular mechanisms underlying these phenotypes have been unclear. Therefore, our data suggest that activation of Atf4-Fgf21 axis contributes to reduced fat mass and increased energy expenditure in nutrient deficiency by enhancing β-oxidation and thermogenesis.
SUPPLEMENTARY FIGURES

Figure S1. Enhanced glucose tolerance in $Atg^{\Delta sm}$ mice fed chow diet. (a) Food intake plotted against body mass with fitted lines of linear regression (left) and food intake adjusted for body mass by ANCOVA (right) in 20-week-old male mice ($n = 9–10$). Food intake was measured during the period of indirect calorimetry. (b) Unadjusted food intake in 20-week-old male mice ($n = 9–10$). (c) Feed efficiency (gain of body weight per cumulated food intake) of male mice between 4 and 16 weeks of age ($n = 11–14$). (d) Energy expenditure (EE) plotted against body mass with fitted lines of linear regression (left) and EE adjusted for body mass by ANCOVA (right) in 20-week-old male mice ($n = 9–10$). (e) Unadjusted EE in 20-week-old male mice ($n = 9–10$). (f) Locomotor activity of 20-week-old male mice ($n = 9–10$). (g) Total run distance of treadmill-exercised 24-week-old mice ($n = 6$). (h) Fasting glucose (left) ($n = 9$) and insulin concentrations (right) ($n = 14$) in 20-week-old male mice fed chow. (i) GTT (left) and ITT (right) in 16-week-old male mice fed chow ($n = 9$). Data are mean ± SEM. *$P < 0.05$, **$P < 0.01$. 

Nature Medicine doi:10.1038/nm.3014
Figure S2. Decreased gain of body weight and improved insulin sensitivity in \textit{Atg7}^{Δsm} mice fed HFD. (a) Gain of body weight in male \textit{Atg7}^{F/F} and \textit{Atg7}^{Δsm} mice fed HFD (\(n = 16–23\)). (b) Body mass and composition of 24-week-old male mice fed HFD for 13 weeks (\(n = 8–10\)). (c) Weights of epididymal, mesenteric and perirenal WAT and interscapular brown adipose tissue (BAT) from HFD-fed mice (\(n = 6\)). (d) Food intake plotted against body mass with fitted lines of linear regression (left) and food intake adjusted for body mass by ANCOVA (right) in male \textit{Atg7}^{F/F} and \textit{Atg7}^{Δsm} mice fed a short-term HFD for 1 week (\(n = 9–10\)). (e) Unadjusted EE and food intake of HFD-fed male mice (\(n = 9–10\)). (f) ITT in \textit{Atg7}^{F/F} and \textit{Atg7}^{Δsm} mice fed HFD for 13 weeks (\(n = 7–10\)). (g) Hepatic glucose production (HGP) in HFD-fed mice during hyperinsulinemic-euglycemic clamp (\(n = 7–8\)). (h) Pyruvate tolerance test (PTT) in mice fed HFD for 13 weeks (\(n = 10–12\)). (i) Relative mRNA level of gluconeogenesis-associated genes in the liver of HFD-fed mice (\(n = 4\)). Data are mean ± SEM. *\(P < 0.05\), **\(P < 0.01\), ***\(P < 0.001\).
Figure S3. Reduced body weight and improved glucose profile in female $Atg7^{Δsm}$ mice fed HFD. (a) Body weight of female $Atg7^{F/F}$ and $Atg7^{Δsm}$ mice fed HFD ($n = 12–18$). (b) Weight of epididymal fat from HFD-fed female mice ($n = 6$). (c) Fasting glucose and insulin concentrations, and HOMA-IR index in female mice fed HFD ($n = 6–13$). (d–f) GTT ($n = 6–13$) (d), ITT ($n = 9–17$) (e), and PTT ($n = 7–15$) (f) in female mice fed HFD. Data are mean ± SEM. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$. 
Figure S4. Improved metabolic profile in Atg7Δsm mice. (a) Relative expression of genes of β-oxidation, lipolysis and thermogenesis in inguinal WAT of HFD-fed mice (n = 3). (b) Ex vivo β-oxidation in extensor digitorum longus muscle of mice fed HFD (n = 6–8). (c) Relative expression of genes of fatty acid and triacylglycerol (TG) synthesis or β-oxidation in GAS muscle of HFD-fed mice (n = 3). (d) Gross image (upper) and TG content (lower) of the liver from mice fed HFD (n = 6–9). (e) Ex vivo β-oxidation in the liver of mice fed HFD (n = 5–7). (f) Serum ALT and AST concentrations in male mice fed HFD for 13 weeks (n = 12–15). (g) Serum glycerol (n = 7) and FFA concentrations (n = 9–12) in fasted mice on HFD. (h) Ucp protein (left) and mRNA levels (right) in GAS muscle of mice fed HFD (n = 3). (i) Immunoblotting for Pgc1α in WAT (perirenal and inguinal) and BAT of mice fed HFD. (j) Rectal temperature in mice fed HFD for 8 weeks (n = 8–9). Data are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. (n.s. indicates not significant).
Figure S5. Increased Fgf21 expression in Atg7Δsm mice and autophagy-deficient cells. (a–d) Serum free T3 (a) (n = 4), adipoQ (b) (n = 10–11), plasma epinephrine or norepinephrine (c) (n = 5), and leptin concentrations (d) (n = 10–12) in Atg7FF and Atg7Δsm mice fed HFD for 13 weeks. (e) Relative Fgf21 mRNA expression in SOL muscle of mice fed chow (n = 3). (f) Relative Fgf21 mRNA expression in the liver, WAT and BAT of Atg7FF and Atg7Δsm mice fed chow (n = 3). (g) Relative Fgf21 mRNA expression in Atg7-null and Tet-off Atg5-null MEFs cultured with or without doxycycline (Dox; 50 ng ml\(^{-1}\)) for 30 days. (h) Relative Atg7 and Fgf21 mRNA expression in C2C12 myotubes infected with adenovirus expressing shCON or shAtg7 for 72 h. (i) Lipolytic effect of Fgf21 on WAT ex vivo. Glycerol release was measured after treatment of epididymal fat from C57BL/6 mice with vehicle (Veh) or recombinant Fgf21 (0.2 and 1 µg ml\(^{-1}\)) for 3 h. Assay was performed in triplicate. (j) Immunoblotting for p-Frs2α, p-Erk, Erk and Hsp90 in the liver of Atg7FF and Atg7Δsm mice fed HFD (left). Relative Egr1 mRNA expression in the liver of mice fed HFD (n = 3) (right). Data are mean ± SEM. *P < 0.05, **P < 0.01 ***P < 0.001.
Figure S6. The role of Fgf21 in improved metabolic profiles of Atg7Δsm mice fed HFD. (a) H&E staining of the liver from male Fgf21+/+Atg7+/+, Fgf21+/+Atg7Δsm, Fgf21+/+Atg7Δsm and Fgf21−/−Atg7Δsm mice fed HFD for 12 weeks. (b–e) Body weight (b), fat weight (c), GTT (d) and ITT (e) in female Fgf21+/+Atg7+/+, Fgf21−/−Atg7+/+, Fgf21+/+Atg7Δsm and Fgf21−/−Atg7Δsm mice fed HFD for 14 weeks (n = 7–11). Data are mean ± SEM. *P < 0.05, **P < 0.01 ***P < 0.001.
Figure S7. The expression of Atf4 and Atf4 target genes in muscle of Atg7Δsm and Mfn1/2Δsm mice or Atg7-null MEFs. (a) Relative mRNA expression of Atf4, asparagine synthetase (Asns), solute carrier family 6, member 9 (Slc6a9), methylenetetrahydrofolate dehydrogenase 2 (Mthfd2) and solute carrier family 3, member 2 (Slc3a2) in GAS muscle of male Atg7F/F and Atg7Δsm mice (n = 3). (b) Relative mRNA expression of Asns, Slc6a9, Mthfd2 and Slc3a2 in wild-type and Atg7-null MEFs. Assay was performed in triplicate. (c) Relative mRNA expression of Atf4 target genes in skeletal muscle of Mfn1/2Δsm mice. The expression of Asns and Mthfd2 genes was increased in skeletal muscle of Mfn1/2Δsm mice. Data are mean ± SEM. *P < 0.05, **P < 0.01.
Figure S8. The role of p62 or Ppara in Fgf21 induction by autophagy deficiency. (a) Immunoblotting for HA-p62 (left) and relative mRNA expression (right) in C2C12 myotubes infected with adenovirus expressing GFP or HA-sqstm1 for 48 h. (b) Luciferase activity of Fgf21 promoter in HEK293 transfected with Atf4 with or without sqstm1 expression vector for 24 h. (c) 2-DG uptake in C2C12 myotubes infected with adenovirus expressing GFP or HA-sqstm1 for 48 h with or without insulin (Ins) treatment. (d) Reporter activity of PPAR response element (PPRE)-luc (left) and Gal4-tk-luc (right) in HEK293 transfected with Ppara (left) and Gal/Ppara (right) vectors, respectively, along with Atf4 plasmid for 24 h. (e) Luciferase activity of Ppara promoter in HEK293 transfected with Atf4 vector for 24 h. (f) Relative Ppara mRNA expression in C2C12 myotubes infected with adenovirus expressing GFP or Atf4 for 36 h. (g) Relative mRNA expression of Ppara in GAS muscle of male Atg7F/F and Atg7Asm mice (n = 3). Data are mean ± SEM (n.s. indicates not significant).
Figure S9. Impaired mtOxPhos gene expression, increased mitochondrial mass and oxidative stress in muscle of Atg7Δsm mice. (a) Relative mRNA expression of mtOxPhos genes in GAS muscle of male Atg7^{+/+} and Atg7^{Δsm} mice (n = 3). (b) ATP content in GAS muscle of Atg7^{+/+} and Atg7^{Δsm} mice (n = 5). (c) Immunoblotting for Tom20 in GAS muscle of Atg7^{+/+} and Atg7^{Δsm} mice. Relative band density was quantified using an ImageJ software. (d) Citrate synthase activity in GAS muscle of Atg7^{+/+} and Atg7^{Δsm} mice (n = 6–8). (e) Immunoblotting for carbonylated protein in GAS muscle of Atg7^{+/+} and Atg7^{Δsm} mice. Data are mean ± SEM. *P < 0.05, **P < 0.01.
Figure S10. The changes of glucose or lipid metabolism and mtOxPhos in Atg7\textsuperscript{Δhep} mice. (a,b) Generation of liver-specific Atg7-null (Atg7\textsuperscript{Δhep}) mice. Relative Atg7 mRNA expression (a) and protein levels of Atg7, Lc3 and p62 (b) in the liver of Atg7\textsuperscript{Δhep} mice (n = 3). (c) Relative mRNA expression of genes associated with fatty acid and triacylglycerol (TG) synthesis or β-oxidation in the liver of Atg7\textsuperscript{Δhep} mice fed chow (n = 3). (d) Plasma TG concentration of Atg7\textsuperscript{F/F} and Atg7\textsuperscript{Δhep} mice after tyloxapol administration (n = 3). (e,f) Relative mRNA expression of mtOxPhos in primary hepatocytes (e) and Atf4 target genes in the liver (f) from Atg7\textsuperscript{F/F} and Atg7\textsuperscript{Δhep} mice fed chow (n = 3). (g) Nonfasting glucose concentration in Atg7\textsuperscript{F/F} and Atg7\textsuperscript{Δhep} mice fed HFD between 9 and 22 weeks of age (n = 5–7). (h) Relative mRNA expression of genes associated with fatty acid and TG synthesis or β-oxidation in the liver of Atg7\textsuperscript{Δhep} mice fed HFD (n = 3). Data are mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
Figure S11. The role of Fgf21 in leucine-deficient (LD) diet-induced metabolic changes. (a) Body weight of male C57BL/6 mice fed control or LD diet between 12 and 15 weeks of age (n = 7–8). Mice on control diet were pair-fed since food intake was decreased by LD diet. (b–d) Fat weight (n = 6) (b), GTT (n = 7–8) (c) and serum Fgf21 concentration (n = 6–7) (d) in male C57BL/6 mice fed control or LD diet for 3 weeks. (e) Relative Fgf21 mRNA expression (n = 3–4) and Atf4 protein level in the liver (left) and GAS muscle (right) of C57BL/6 mice fed control or LD diet for 3 weeks. (f) Relative mRNA expression of mtOxPhos genes in the liver of C57BL/6 mice fed LD diet for 3 weeks (n = 3). (g) Ex vivo β-oxidation in WAT and BAT of C57BL/6 mice fed control or LD diet for 10 days (n = 8–10). (h) Body weight in male Fgf21+/+ and Fgf21−/− mice fed control or LD diet between 12 and 15 weeks of age (n = 5–9). (i,j) Fat weight (i) and GTT (j) in male Fgf21+/+ and Fgf21−/− mice fed control or LD diet for 3 weeks (n = 5–9). Data are mean ± SEM. *P < 0.05, **P < 0.01 ***P < 0.001.
SUPPLEMENTARY METHODS

**Body composition and analysis of energy balance.** Fat and lean body masses were measured by a \(^1\)H minispec system (LF90II; Bruker Optik) in mice fed chow or HFD. Activity, food consumption, oxygen consumption, and energy expenditure were assessed in a metabolic monitoring system (CLAMS: Columbus Instruments) for 4 days (2 days of acclimation followed by 2 days of measurement) employing 20- or 24-week-old mice fed chow diet or HFD as previously described\(^4\). Locomotor activity was measured by counting the number of infrared beam breaks on x- and z-axes during the measurement period. Rectal temperature was measured using a Testo 925 electronic rectal thermometer (Testo).

**Hyperinsulinemic-euglycemic clamp.** Seven days prior to the hyperinsulinemic-euglycemic clamp studies, indwelling catheters were placed into the right internal jugular vein. After overnight fast, [\(^3\)-\(^3\)H]-glucose (HPLC purified; PerkinElmer) was infused at a rate of 0.05 \(\mu\)Ci per min for 2 h to assess the basal glucose turnover. Following the basal period, hyperinsulinemic-euglycemic clamp was conducted for 140 min with a primed/continuous infusion of human insulin (126 pmol per kg during priming, 18 pmol per kg per min during infusion) (Eli Lilly), while plasma glucose was maintained at a basal concentration (~6.7 mM) as described\(^4\). Throughout the clamps, [\(^3\)-\(^3\)H]-glucose was infused at a rate of 0.1 \(\mu\)Ci per min to estimate insulin-stimulated whole-body glucose flux, and 2-deoxy-D-[\(^1\)\(^4\)C]-glucose (2-[\(^1\)\(^4\)C]-DG; PerkinElmer) was injected as a bolus at the 85\(^{th}\) minute of the clamp to estimate the rate of insulin-stimulated tissue glucose uptake. Blood samples (10 \(\mu\)l) were taken at the end of the
basal period and during the last 45 min of the clamp for the measurement of plasma $^3$H and $^{14}$C activities.

**Glucose flux calculation:** To determine plasma $^3$H and $^{14}$C activities, plasma was deproteinized with ZnSO$_4$ and Ba(OH)$_2$, dried to remove $^3$H$_2$O, resuspended in water and counted in scintillation fluid (Ultima gold, PerkinElmer) using a Beckman scintillation counter. The rates of basal and insulin-stimulated whole-body glucose flux were determined as the ratio of the [3-$^3$H]-glucose infusion rate (disintegrations per minute [DPM]) to the specific activity of plasma glucose (DPM per mg) at the end of the basal period and during the final 30 min of the clamp experiment, respectively. Hepatic glucose production (HGP) was determined by subtracting the glucose infusion rate from the total glucose appearance rate. The plasma concentration of $^3$H$_2$O was determined by the difference between $^3$H counts with and without drying. Whole-body glycolysis was calculated from the rate of the increase in plasma $^3$H$_2$O concentration divided by the specific activity of plasma $^3$H-glucose, as previously described$^5$. Whole-body glycogen synthesis was estimated by subtracting whole-body glycolysis from whole-body glucose uptake, assuming that glycolysis and glycogen synthesis account for the majority of insulin-stimulated glucose uptake$^6$. To determine individual tissue glucose uptake, tissue samples were homogenized, and the supernatants were subjected to an ion-exchange column to separate tissue $^{14}$C-2-DG-6-phosphate (2-DG-6-P) from 2-DG. Tissue glucose uptake was calculated from the area under the curve of plasma $^{14}$C-2-DG profile for the last 45 min of the clamp and muscle $^{14}$C-2-DG-6-P content, as previously described$^5$.

**In vivo fatty acid oxidation.** *In vivo* fatty acid oxidation rate was determined by the rate of $^{14}$CO$_2$ production after infusion of 3 μCi of [1-$^{14}$C]-oleic acid (PerkinElmer) as previously
described. Briefly, 300 μg of cold oleic acid (Sigma) conjugated to fatty acid-free BSA (Sigma) was injected intraperitoneally into mice with [1-\(^{14}\)C]-oleic acid (3 μCi) at 9 AM. Mice were put in metabolic chambers connected with 1 N NaOH trap to capture expired \(^{14}\)CO\(_2\). \(^{14}\)C radioactivity from NaOH trap was counted at 30-min interval over the next 4 h, and the slope for the initial 2 h was plotted because captured radioactivity is saturated after 2 h.

**Ex vivo fatty acid oxidation.** WAT, BAT, skeletal muscle (extensor digitorum longus) and the liver were quickly removed from mice and placed in 25-ml flasks fitted with center wells containing 1 N NaOH and a filter paper strip to trap \(^{14}\)CO\(_2\). Flasks were capped with bottle stoppers. Incubation media contained 3 ml of Krebs-Ringer phosphate buffer, 2 μCi of [1-\(^{14}\)C] oleic acid and cold oleic acid (0.6 mM final concentration) in complex with BSA. Tissues were incubated in shaking water bath at 37 °C for 60 min (WAT and skeletal muscle) or 30 min (BAT and liver). After shaking incubation, 1 ml of 0.5 N sulfuric acid was injected into the media to release \(^{14}\)CO\(_2\). Flasks were maintained at 50 °C for 3 h to transfer \(^{14}\)CO\(_2\) to NaOH in the center well. After acid treatment, contents of the center well were transferred to scintillation fluid and \(^{14}\)C radioactivity was counted.

**Ex vivo lipolysis assay.** Epididymal fat pads were removed fresh from mice and finely minced with ultra-thin razor blades. Fragments of adipose tissues were gently washed once by inverting and centrifuged at 100 × g for 5 min in Krebs-Ringer bicarbonate buffer (KRBB), pH 7.4 (Sigma). The fragments (100 mg) were transferred to KRBB supplemented with 25 mM HEPES and 1% BSA. Samples were treated with vehicle (sterile water) or recombinant Fgf21 (BioVision) of the final concentrations of 0.2–1 μg ml\(^{-1}\) at 37 °C for 3 h. Glycerol released from...
adipose tissues was then measured using a Glycerol Determination Kit (Sigma).

**Treadmill exercise.** The treadmill test was performed using the Exer-6M (Columbus Instruments). Twenty-four-week-old male mice were warmed up at a speed of 5 m per min for 10 min. Every subsequent 10 min, the speed was increased by 5 m per min. Then, mice ran until exhaustion at a maximum speed of 25 m per min. Exhaustion was defined as the inability to continue regular treadmill running despite repeated electric prodding to the mice. Running time was measured, and running distance was calculated.

**Microarray analysis.** Total RNA was extracted with TRIzol (Invitrogen) and purified using RNeasy columns (Qiagen) according to the manufacturer’s instruction. Microarray analysis was carried out by Macrogen Inc. Briefly, biotinylated complementary RNAs were amplified and purified using an Illumina RNA amplification kit (Ambion) according to the manufacturer’s instruction. Labeled cRNA samples were hybridized to each Mouse-8 Expression Bead Array according to the manufacturer's instruction (Illumina). Detection of array signal was carried out using FluoroLink streptavidin-Cy3 (GE Healthcare Bio-Sciences). Arrays were scanned with an Illumina bead array Reader confocal scanner, and the scanned images were analyzed using an Illumina BeadStudio v3.1.3 software (Gene Expression Module v3.3.8).

**Plasmid constructs.** pcDNA3-HA-Atf4 and pcDNA3-HA-p62 were constructed by inserting human \(ATF4\) and \(p62\) fragments, respectively, into EcoRI/XhoI-digested pcDNA3-HA vector. pGL3B-\(PPAR\alpha\) (-2150/+300) was constructed by inserting PCR fragment of human \(PPAR\alpha\)
promoter into KpnI/MluI-digested pGL3B vector. PPRE-luc, Gal4-tk-luc, pcDNA3/Parα and pCMX/Gal4N/Parα have been described8. Nucleotide sequence of the 5'-flanking region of Fgf21 promoter was scanned, and two putative ATF4 binding sites (ATF4REs) were identified based on the nucleotide sequence. pGL3B-Fgf21(–2078/+129), pGL3B-Fgf21(–853/+129) (ATF4RE1) and pGL3B-Fgf21(–107/+129) (ATF4RE1/2) deletion mutant reporters were constructed by inserting respective PCR fragments amplified from C57BL/6 mouse liver genomic DNA into KpnI/BglII-digested pGL3B luciferase reporter. pGL3B-Fgf21(–1370/+129) vector has been described9. To create an ATF4mutRE1 point mutant reporter, 5’-CATCA-3’ sequence (–1024 to –1020) of pGL3B-Fgf21(–1370/+129) vector was mutated to 5’-TCGAG-3’ sequence by a DpnI-based site-directed mutagenesis method. An ATF4mutRE1/2 point mutant reporter was constructed by creating additional mutation at another 5’-CATCA-3’ sequence (–136 to –132). Nucleotide sequences of all plasmids were confirmed by automatic sequencing.

**Generation of adenovirus.** Adenoviruses expressing HA-Atf4, HA-p62 or shAtg7 were generated by homologous recombination between a linearized transfer vector (pAd-Track-CMV-HA-Atf4, Ad-Track-CMV-HA-p62 or Ad-Track-ΔCMV-shAtg7) and an adenoviral backbone vector (pAd-Easy) as described10. Mouse shAtg7 target sequences were as follows: 5’-AAGGTCGTGTCTGTCAAGTGC-3’. Adenovirus was amplified in 293AD cells and purified by CsCl density gradient centrifugation.

**Cell culture.** C2C12 and HEK293 cells were obtained from the American Type Culture Collection. Atf4-null or wild-type MEFs and eIF2αS/S or eIF2αA/A MEFs were generous gifts.
from D. Ron and R.J. Kaufman, respectively. *Atg7*-null or wild-type MEFs have been described\(^\text{11}\). Tet-off *Atg5*-null MEFs\(^\text{12}\) were gifted from N. Mizushima. Primary mouse hepatocytes were isolated from 16-week-old *Atg7*\(^{F/F}\) and *Atg7*\(^{Δhep}\) mice by portal vein cannulation and collagenase digestion. After purification of hepatocytes with Percoll (GE Healthcare Bio-Sciences), cells were plated and maintained in Medium 199 supplemented with 10% FBS. All cells were maintained at 37 °C in a humid atmosphere of 5% CO\(_2\).

**siRNA transfection and luciferase assay.** *Aft4* siRNA (si*Aft4*) and *GFP* siRNA (siCON) were purchased from Bioneer Inc. (si*Aft4*, 5'-GCCUAGGUCUCUUAGAUGAdTdT-3'; siCON, 5'-GCAUCAAGGUGAACUUCAAdTdT-3'). *Atg7*-null or wild-type MEFs were cultured in 6-well plates and transfected with si*Aft4* (100 nM) or siCON (100 nM) using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instruction. For luciferase assay, HEK293 or C2C12 cells were plated in 24-well culture plates and transfected with a firefly reporter vector (0.2 μg) and Renilla reporter vector (0.01 μg), together with indicated expression plasmids (0.2 μg) using JetPEI (PolyPlus) reagent according to the manufacturer's instruction. pcDNA3 empty vector was added to the transfection to make the same total amount of plasmid DNA per transfection. After 24 h of transfection, cells were lysed in a cell culture lysis buffer (Promega), and luciferase activity was measured. Firefly luciferase activity was normalized to Renilla luciferase activity. All assays were performed at least in triplicate.

**RNA isolation, RT-PCR and real-time RT-PCR.** Total RNA from various cells or tissues was prepared using TRIzol (Invitrogen) and purified using a RNA clean up kit (GeneAll) according to the manufacturer’s instruction. cDNA was synthesized from 2 μg of total RNA using MMLV-
RT (Moloney Murine Leukaemia Virus) reverse transcriptase (Promega) and oligo(dT) primer at 42 °C for 1 h. An aliquot (1/30 vol) of cDNA was then subjected to PCR amplification using specific primers. Real-time RT-PCR was performed using SYBR Green I (Takara) in ABI Prism 7000 (Applied Biosystems). All expression values were normalized to L32 mRNA level.

Real-time RT-PCR primers used (5’ to 3’):

- **Acaca**
  - F: CCAGGCCATGTTGAGACGC
  - R: ATCACAGAGCGGACGCCATC

- **Acacb**
  - F: CGTGGTAGACACAGCTGAG
  - R: CCCAGGTAAGCAGGAGATA

- **Acadl**
  - F: GGGAATGAAAGCCTACAGCA
  - R: AGAATCCGATTAGCTGCT

- **Acadm**
  - F: AGGTTCAGATGCAATGG
  - R: AGAATCCGCATTAGCTGCT

- **AdipoQ**
  - F: GATGTTGGAATGACAGGAG
  - R: TACACCAGTGATGTAAGAGA

- **Asns**
  - F: AACGCTTGATGACAGACCCG
  - R: CCTTTCTAGCGGAGCCAGGAGA

- **Atf4**
  - F: AGCAAAAACAGACACAGGAGG
  - R: ACTCTCTTCTTCCCCCTTG

- **Atg7**
  - F: TGTGGAGCTGATGCTCTG
  - R: TGATGGACAGGGTAAGACC

- **Atp5o**
  - F: TCTGGCGCCAGTAGTCTCTT
  - R: AGATGATACCCTGGGTGTTG

- **Cidea**
  - F: GCCGTGTTAAGGAATCTGCT
  - R: TGCTCTTCTGTATCGCCCAGT

- **Cox5b**
  - F: AGGCAGCTTCAGCGTACCAAG
  - R: GGTGGGGAACCCAGGTTTA

- **Cpt1a**
  - F: CCGATCATGTTAAGCAAGCAAG
  - R: TGGAGCAGGATTTGGCATA

- **Cpt1b**
  - F: CCTTATCTCCTGCAAGAATG
  - R: TCGTAAGTCCAGGCGAAGCT

- **Cyacs**
  - F: TACCCACTCAGAAAACACACA
  - R: GTCTGAAAGTCAGCAGGTG

- **Dgat2**
  - F: TCATGGGTTGTCTGTTGTTA
  - R: CAGAGTGAAACCACCAGCCAAACA

- **Dio2**
  - F: GGGACTTCCCTCCTGTCTTT
  - R: CCAACTCTCGGACTTTCTGTA
<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Egr1</td>
<td>GAGAACCGTACCCAGCAGCC</td>
<td>CGATCGCAGGACTGATACAG</td>
</tr>
<tr>
<td>Fasn</td>
<td>CTCCGTGGACCTTATCATA</td>
<td>CTGGGAGAGGTTGTAGTACC</td>
</tr>
<tr>
<td>Fgf21</td>
<td>TACACAGATGACGACCAAGA</td>
<td>GGCTTCAGACTGATACAT</td>
</tr>
<tr>
<td>G6pc</td>
<td>TCCTCTTCTCCATCTGGTTC</td>
<td>TATACACGCTCTGGTACCT</td>
</tr>
<tr>
<td>Igfbp2</td>
<td>AGAAGTGTAGAACACAGC</td>
<td>GCACCTGGTTACCAGAG</td>
</tr>
<tr>
<td>Il15</td>
<td>GAATACATGACGACGACG</td>
<td>TTGACCTGTTAGGACGACT</td>
</tr>
<tr>
<td>Il16</td>
<td>TTGCCTTCTGAGACTGATGC</td>
<td>GTATCTCTCTGAGACGACT</td>
</tr>
<tr>
<td>L32</td>
<td>CAGTCAGACCATATGGA</td>
<td>TAGAGGACACATGAGGC</td>
</tr>
<tr>
<td>Lipe</td>
<td>AAGGACTTGAGACCTACGA</td>
<td>TTGACTATGGGAGCTGTA</td>
</tr>
<tr>
<td>Mgl1</td>
<td>GACGGACAGTACCTCTTTTG</td>
<td>AGAAAGTAGGTTGCCCT</td>
</tr>
<tr>
<td>Mthfd2</td>
<td>AGCAGCAGATGCTTGACGAC</td>
<td>CACCAGGGACGGAGTGATA</td>
</tr>
<tr>
<td>Myh1</td>
<td>CTGGATGCTGATGATTAGG</td>
<td>TGGTATTTTCCTGATC</td>
</tr>
<tr>
<td>Myh2</td>
<td>GAAAGCTAAGAAGAGCATCA</td>
<td>GTTATCCACAAATCCT</td>
</tr>
<tr>
<td>Myh4</td>
<td>CTGGGAACAGACGAGAGGAG</td>
<td>TGTAAGGTAGTTTCCTC</td>
</tr>
<tr>
<td>Myh7</td>
<td>AAGAAGAAGATGGAGACGA</td>
<td>AGGTTTCTCTGCTT</td>
</tr>
<tr>
<td>Ndufb5</td>
<td>TCCTAGACTCGAGTGGAA</td>
<td>AACTTCCTGTGCTT</td>
</tr>
<tr>
<td>Pck1</td>
<td>GATGGGCTATCTGGTCTGG</td>
<td>CAGCCACCTCTCCTCT</td>
</tr>
<tr>
<td>Pnpla2</td>
<td>CATGATGCTGCTGATGCTG</td>
<td>GTGAGAGGTTGGTT</td>
</tr>
<tr>
<td>Ppara</td>
<td>GGATGTCACTACACATGCAAATCC</td>
<td>TCACAGAACCCTCCTCATG</td>
</tr>
<tr>
<td>Pparg</td>
<td>ATCCCTGGTTGCTACATTAACCT</td>
<td>GCTCATCAAAGTAC</td>
</tr>
<tr>
<td>Ppargc1a</td>
<td>ATACGGCAAGAGCAGAGGA</td>
<td>CTCAAGAGCAGCGAAAG</td>
</tr>
<tr>
<td>Prdm16</td>
<td>AGCCCTGCGCCCAACCTGTC</td>
<td>TGACCCTGCCGCTT</td>
</tr>
<tr>
<td>Scd1</td>
<td>TGGAAATGCTTCTGAGATG</td>
<td>CCAGCAGCTTCTGGAT</td>
</tr>
<tr>
<td>Sle3a2</td>
<td>GGGGAGCGTACTGACCT</td>
<td>CTGAAGGCAAGCTC</td>
</tr>
</tbody>
</table>

*Nature Medicine doi:10.1038/nm.3014*
<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Slc6a9</td>
<td>(F): GTTGCGCTTTGTTTCTCCG</td>
<td>(R): TCTGCTTGGCTTTGTGGCAT</td>
</tr>
<tr>
<td>Srebf1c</td>
<td>(F): TGCAGCTTTGCTCTACCATA</td>
<td>(R): TGCTGGAGCTGACAGAGAAA</td>
</tr>
<tr>
<td>Tnf</td>
<td>(F): CCTGTAGCCCACGTGCTAGC</td>
<td>(R): TTGACCTCAGCGCTGAGTTG</td>
</tr>
<tr>
<td>Ucp1</td>
<td>(F): TATCATCACCTCCCGCTG</td>
<td>(R): GTCATATGTTACCAGCTCTG</td>
</tr>
<tr>
<td>Ucp2</td>
<td>(F): CTGCAGGATGACACCACAG</td>
<td>(R): AAAGGTGCCTCCCGAGATT</td>
</tr>
<tr>
<td>Ucp3</td>
<td>(F): CCTCTACGACTGTCAGGTC</td>
<td>(R): GACAGGGGAAGTTGTCAGTA</td>
</tr>
<tr>
<td>Uqcrb</td>
<td>(F): ACTTACCAGAAGGCAGCG</td>
<td>(R): TGCCCACCTCTCTCTCTCTCT</td>
</tr>
</tbody>
</table>

**Antibodies.** For immunoblot analysis, Santa Cruz antibodies were used: Hsp90 (sc-7947, 1:2,000 dilution), β-actin (sc-47778, 1:1,000 dilution), Atf4 (sc-200, 1:1,000 dilution), Tom20 (sc-11415, 1:1,000 dilution), Pgc1α (sc-13067, 1:1,000 dilution). Cell Signaling antibodies were used: Atg7 (#2631, 1:1,000 dilution), HA (#2367, 1:1,000 dilution), total Eif2α (#9722, 1:2,000 dilution), phospho-Eif2α Ser51 (#3597, 1:1,000 dilution), total Erk (#4695, 1:2,000 dilution), phospho-Erk Thr202/Tyr204 (#4370, 1:1,000 dilution), phospho-Frs2α Tyr196 (#3864, 1:1,000 dilution). Calbiochem antibodies were used: Ucp1 (662045, 1:1,000 dilution), Ucp2 (144157, 1:1,000 dilution). Millipore antibody was used: Ucp3 (AB3046, 1:1,000 dilution). Novus Biologicals antibody was used: Lc3 (NB100-2331, 1:1,000 dilution). R&D Systems antibody was used: Fgf21 (AF3057, 1:1,000 dilution). For immunohistochemical staining of β-cells, insulin-specific antibody (A0564, Dako, 1:100 dilution) was used. For immunofluorescent staining of muscle fibers, p62-specific (GP62-C, Progen, 1:100 dilution) and ubiquitin-specific (Z0458, Dako, 1:100 dilution) antibodies were used.

**Immunoblot analysis.** Cells and tissues were lysed in a radio-immunoprecipitation assay buffer
[RIPA; 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% (v/v) NP-40 (Nonidet P-40), 0.25% sodium deoxycholate, 1 mM PMSF and protease inhibitors (Roche)] for 30 min on ice, and whole lysates were obtained by subsequent centrifugation at 13,000 × g for 20 min at 4 °C. Protein concentration was determined by the Bradford assay (Bio-Rad). Lysates (50–100 μg of protein) were subjected to SDS/PAGE (8–12% gels) and transferred to PVDF membranes (Millipore). Membranes were then incubated with primary antibodies in Tris-buffered saline containing 0.05% Tween-20 (TBST) supplemented with 5% (w/v) non-fat dry milk. Bands were visualized using an enhanced chemiluminescence (ECL) system (Amersham Biosciences). Protein carbonylation was determined using an OxyBlot Protein Oxidation Detection Kit (Millipore). Relative band densities were quantified using an NIH ImageJ Software.

**Purification of mitochondria and oxygen consumption.** Skeletal muscle tissues were homogenized in a mitochondrial isolation buffer (pH 7.4) containing 50 mM sucrose, 200 mM mannitol, 5 mM potassium phosphate, 1 mM EGTA, 5 mM MOPS, 0.1% BSA and protease inhibitors using a medium-fitting glass-teflon Potter-Elvehjem homogenizer. Resultant homogenate was centrifuged at 1,000 × g for 5 min at 4 °C. Supernatant was centrifuged again at 10,000 × g for 10 min at 4 °C. Mitochondrial pellets were collected and diluted in 3 volumes of mitochondrial isolation buffer. Mitochondria oxygen uptake was measured using a Clark-type oxygen electrode (Instech) in a 600 μl air-saturated chamber at room temperature. The respiration medium consisted of 145 mM KCl, 30 mM HEPES, 5 mM KH2PO4, 3 mM MgCl2, 0.1 mM EGTA, and 0.1% BSA (pH 7.4). Mitochondrial state 4 respiration was determined using 5 mM glutamate/malate as substrates. State 3 (active) respiration was measured after adding 0.5 mM ADP to the medium. Oxygen uptake was expressed in nanomoles of O2 per minute per
milligram of protein.
SUPPLEMENTAL REFERENCES


